Subgroup analysis results: Remission at week 8, stratified by baseline Mayo score, extensive colitis, concomitant medications, baseline CRP level, and weight tertiles
| Placebo N=130 | ADA 80/40 N=130 | ADA 160/80 N=130 | |
| Mayo <10, N | 83 | 81 | 85 |
| Remission, n (%) | 10 (12.0) | 11 (13.6) | 17 (20.0) |
| Difference from placebo* (95% CI) | 1.5 (–8.7 to 11.8) | 8.0 (–3.1 to 19.0) | |
| Mayo ≥10, N | 47 | 49 | 45 |
| Remission, n (%) | 2 (4.3) | 2 (4.1) | 7 (15.6) |
| Difference from placebo (95% CI) | −0.2 (−8.2 to 7.8) | 11.3 (−0.8 to 23.4) | |
| Extensive colitis, N | 73 | 70 | 60 |
| Remission, n (%) | 11 (15.1) | 7 (10.0) | 12 (20.0) |
| Difference from placebo (95% CI) | −5.1 (−15.9 to 5.7) | 4.9 (−8.1 to 18.0) | |
| No extensive colitis, N | 57 | 60 | 70 |
| Remission, n (%) | 1 (1.8) | 6 (10.0) | 12 (17.1) |
| Difference from placebo (95% CI) | 8.2 (−0.1 to 16.6) | 15.4 (5.9 to 24.9) | |
| Corticosteroid (without IMM), N | 55 | 48 | 48 |
| Remission, n (%) | 6 (10.9) | 5 (10.4) | 10 (20.8) |
| Difference from placebo (95% CI) | −0.5 (−12.6 to 11.7) | 11.3 (−3.0 to 25.7) | |
| IMM† (without corticosteroid), N | 18 | 25 | 28 |
| Remission, n (%) | 0 | 2 (8.0) | 6 (21.4) |
| Difference from placebo (95% CI) | 8.7 (−2.8 to 20.2) | 20.7 (5.9 to 35.4) | |
| IMM + corticosteroid, N | 34 | 26 | 23 |
| Remission, n (%) | 2 (5.9) | 4 (15.4) | 2 (8.7) |
| Difference from placebo (95% CI) | 8.4 (−6.8 to 23.6) | 4.1 (−11.2 to 19.5) | |
| No corticosteroid + no IMM, N | 23 | 31 | 31 |
| Remission, n (%) | 4 (17.4) | 2 (6.5) | 6 (19.4) |
| Difference from placebo (95% CI) | −10.4 (−27.5 to 6.7) | −1.0 (−20.5 to 18.5) | |
| Aminosalicylates, N | 98 | 98 | 105 |
| Remission, n (%) | 11 (11.2) | 7 (7.1) | 18 (17.1) |
| Difference from placebo (95% CI) | −4.1 (−12.1 to 4.0) | 5.9 (−3.6 to 15.5) | |
| No aminosalicylates, N | 32 | 32 | 25 |
| Remission, n (%) | 1 (3.1) | 6 (18.8) | 6 (24.0) |
| Difference from placebo (95% CI) | 15.6 (0.8 to 30.4) | 20.9 (3.1 to 38.7) | |
| CRP <10 mg/l, N | 95 | 87 | 101 |
| Remission, n (%) | 7 (7.4) | 9 (10.3) | 21 (20.8) |
| Difference from placebo (95% CI) | 3.0 (−5.3 to 11.3) | 13.4 (3.9 to 22.9) | |
| CRP ≥10 mg/l, N | 32 | 40 | 25 |
| Remission, n (%) | 4 (12.5) | 4 (10.0) | 2 (8.0) |
| Difference from placebo (95% CI) | −2.5 (−17.3 to 12.3) | −4.5 (−20.1 to 11.1) | |
| Weight < 70.0 kg, N | 35 | 40 | 45 |
| Remission, n (%) | 5 (14.3) | 6 (15.0) | 11 (24.4) |
| Difference from placebo (95% CI) | 0.7 (−15.3 to 16.7) | 10.2 (−6.9 to 27.2) | |
| Weight ≥70.0 kg, <82.0 kg, N | 43 | 48 | 33 |
| Remission, n (%) | 3 (7.0) | 3 (6.3) | 8 (24.2) |
| Difference from placebo (95% CI) | −0.7 (−11.0 to 9.5) | 17.3 (0.8 to 33.8) | |
| Weight ≥82.0 kg, N | 52 | 42 | 52 |
| Remission, n (%) | 4 (7.7) | 4 (9.5) | 5 (9.6) |
| Difference from placebo (95% CI) | 1.8 (−9.6 to 13.3) | 1.9 (−8.9 to 12.7) |